NPCE

NeuroPace Inc

Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001528287 Healthcare & Medical Devices

$13.06 +0.07 (+0.50%)

Oct 27 4:00 PM ET · prev $12.99

Market cap

$443.1M

Small cap

Consensus

Buy

94% Buy or better · 16 analysts

Median target

$20.00

+53% · range $18.00–22.00

Next earnings

Nov 10

in 14 days

1 year

+23.2%

from $10.60 · Oct 27

30 days

−7.7%

from $14.15

52-week range

$9.40–19.29

−32% from high · low Nov 3

Avg volume 20D

101.0K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$399.3K

0 buyers · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 2 reports · latest

Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 2/2 ·Next Earnings date, Nov 10, 2026

Strongest BULLISH NeuroPace reported Q1 2026 non-GAAP revenue (excluding DIXI) of $22.0M, up 20.1% YoY, and raised full-year…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Dec 15 1 insider sell $399.3K at $15.97
R May 12 NeuroPace reported Q1 2026 non-GAAP revenue (excluding DIXI) of $22.…
A Jul 23 Mizuho initiates
A Sep 18 Keybanc initiates

Signal stack

Where each data set points today.

InsidersBEARISH

1 insider sold $399.3K.
InstitutionsMIXED

Q2 2026: 11 added (0 new), 10 trimmed or exited.
AnalystsBULLISH

15 of 16 rate it Buy or better. Every target is above the price.
TrendDOWNTREND

5% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
D. E. Shaw & Co., Inc.	DOUBLED	161,081	$2.6M
CITADEL ADVISORS LLC	ADD	128,800	$2.0M
RENAISSANCE TECHNOLOGIES LLC	TRIM	111,699	$1.8M
Man Group plc	ADD	84,073	$1.3M
SEI INVESTMENTS CO	TRIM	62,177	$988.0K
Connor, Clark & Lunn Investment Management Ltd.	TRIM	28,692	$455.9K
WELLS FARGO & COMPANY/MN	ADD	27,417	$435.7K
PRICE T ROWE ASSOCIATES INC /MD/	ADD	21,764	$346.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts

Buy 94% rate it Buy or better

Strong Buy4Buy11Hold1Sell0Strong Sell0

12-month targets · 10 analysts

$13.06 $18.00 $20.00 $22.00

Price is below the lowest target. Median implies +53%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 18, 2026	Keybanc INITIATE	INITIATE	Overweight
Jul 29, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jul 23, 2026	Mizuho INITIATE	INITIATE	Outperform
May 15, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4

bought · 0 insiders

$399.3K

sold · 1 insider

Date	Insider	Type	Value
Sep 24, 2026	Morrell Martha CHIEF MEDICAL OFFICER	TAX W/H	$4.7K
Sep 20, 2026	Williams Patrick F. Chief Financial Officer	TAX W/H	$16.6K
Sep 3, 2026	Becker Joel CHIEF EXECUTIVE OFFICER	TAX W/H	$19.3K
Aug 27, 2026	Becker Joel CHIEF EXECUTIVE OFFICER	TAX W/H	$15.9K
Aug 27, 2026	Morrell Martha CHIEF MEDICAL OFFICER	TAX W/H	$5.1K
Jun 24, 2026	Morrell Martha CHIEF MEDICAL OFFICER	TAX W/H	$5.4K
Jun 19, 2026	Kumar Rakhi Director	AWARD	$15.5K
Jun 19, 2026	Geiger Uri Director	AWARD	$12.3K

Earnings setup

Estimates

Nov 10

reports in 14 days

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	-$0.07	-$0.14–-$0.04	+3.6%	$28.4M
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only